PGR and neoplasm: In an exploratory analysis of only those patients with ER-positive and PgR-positive tumours (approximately 42% of the trial population), the median TTP was 11.4 months for fulvestrant and 8.5 months for tamoxifen (HR: 0.85; 95% CI, 0.63–1.15; P=0.31) and OR was significantly higher for fulvestrant compared with tamoxifen (44.3 vs 29.8%; P=0.02).